Why predictive intelligence is changing the Medical Science Liaison model

Tern plc

Medical Science Liaisons have traditionally been the scientific connection between pharmaceutical companies and healthcare professionals. Their role is centred on non promotional dialogue, explaining clinical evidence, answering scientific questions and collecting feedback from the field. For many years this model relied on structured engagement plans, established opinion leaders and scheduled interactions at congresses or advisory boards.

However, the information environment surrounding modern healthcare has changed significantly. Scientific debate now develops continuously across digital platforms, academic publications and professional networks. Clinicians discuss emerging evidence faster and across more channels than before.

The challenge for Medical Affairs teams is not simply operational. Pharmaceutical companies increasingly rely on Medical Affairs to provide early visibility on shifts in clinical thinking, treatment behaviour and emerging scientific questions. If insight from the field arrives too slowly, the organisation may miss early signals that influence how therapies are positioned, studied or adopted in practice.

Traditional MSL planning typically focuses on a fixed group of recognised experts. While these relationships remain valuable, influence in healthcare conversations is now more fluid. New voices often emerge quickly around specific research topics, clinical questions or therapeutic developments. Identifying these individuals early can be important for companies seeking to understand how medical narratives are evolving.

Predictive intelligence offers a way to address this gap. By analysing large volumes of healthcare discussion, scientific publication activity and other behavioural signals, data models can identify patterns that indicate where medical conversations are forming and who is shaping them. This allows Medical Affairs teams to prioritise engagement based on current influence rather than relying solely on historical relationships.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern Plc reports 2025 results and outlines portfolio value strategy

Tern plc has reported audited annual results, outlined portfolio developments and convened a General Meeting for 9 July 2026.

Device Authority targets enterprise IoT security demand through Xalient partnership

Device Authority has partnered with Xalient to bring KeyScaler into managed enterprise security services, strengthening its position in scalable IoT and OT device identity management.

Talking Medicines targets a clearer view of GLP-1 and cancer care demand

Talking Medicines is showing why real-world healthcare conversations matter for investors tracking GLP-1, oncology and the next stage of life sciences market positioning.

GLP-1 cancer signals add a new investor angle

Early oncology signals from ASCO 2026 add a new investor angle to the GLP-1 story, with further research needed before clinical or commercial conclusions can be drawn.

Device Authority expands enterprise reach through IoT security partnership

Device Authority’s partnership with Xalient strengthens its enterprise IoT security positioning as regulated industries look for scalable, automated ways to manage connected device risk.

Pharma engagement shifts from reach to relevance

Pharma engagement is moving from broad reach to relevant messaging across connected patient journeys.

Search